Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

Sarepta Therapeutics CEO Doug Ingram is taking the high road.

In remarks Thursday on a quarterly earnings call, Ingram refused to criticize the Food and Drug Administration for rejecting Sarepta’s Duchenne muscular dystrophy drug Vyondys 53.